Clinical Trial Update: A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) [Phase 1]

View source ↗

Summary

A phase 1 clinical trial evaluating the safety and efficacy of AUR108 in patients with relapsed advanced lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• AUR108

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Relapsed Advanced Lymphomas | Phase 1 | Status: RECRUITING